Top

Published in:

01-01-2021 | Colchicine

Highlights from the European society of cardiology congress 2020

Authors: Pooneh Nabavizadeh, Dylan L. Steen

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2021

Excerpt

After another exciting conference, this article highlights some of the many studies presented. Below, we start with some of the clinically impactful studies that demonstrated statistically significant primary endpoint results. …

Kirchhof P, Camm AJ, Goette A et al (2020) Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. NEJM 383(14):1305–1316CrossRefPubMed

Bunch TJ, Steinberg BA (2020) Revisiting rate versus rhythm control in atrial fibrillation- timing matters. NEJM 383(14):1383–1384CrossRefPubMed

Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. NEJM 383(15):1413–1424CrossRefPubMed

Jarcho JA (2020) More evidence for SGLT2 inhibitors in heart failure. NEJM 383(15):1481–1482CrossRefPubMed

Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759–769CrossRefPubMed

Papadakis M, Basu J, Sharma S (2020) Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. Lancet 396(10253):736–737CrossRefPubMed

Nidorf SM, Fiolet ATL, Mosterd A et al (2020) Colchicine in Patients with Chronic Coronary Disease. NEJM. https://doi.org/10.1056/NEJMoa2021372CrossRefPubMed

Liuzzo G, Patrono C (2020) Low-dose colchicine a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa782CrossRefPubMed

Brouwer J, Nijenhuis VJ, Delewi R et al (2020) Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. NEJM 383(15):1447–1457CrossRefPubMed

10.

Lopes RD, Macedo AVS, de Barros E, Silva PGM et al (2020) Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–The BRACE CORONA Trial. Am Heart J. 226:49–59. https://doi.org/10.1016/j.ahj.2020.05.002CrossRefPubMedPubMedCentral

11.

Mathur A, Arnold R, Assmus B et al (2017) The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. Eur J Heart Fail 19(11):1545–1550. https://doi.org/10.1002/ejhf.829CrossRefPubMed

12.

Mathur A, Fernández-Avilés F, Bartunek J et al (2020) The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J 41(38):3702–3710. https://doi.org/10.1093/eurheartj/ehaa651CrossRefPubMedPubMedCentral

13.

Tarantini G, Mojoli M, Varbella F et al (2020) Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials 21(1):966. https://doi.org/10.1186/s13063-020-04859-1CrossRefPubMedPubMedCentral

14.

Tarantini G, Mojoli M, Varbella F et al (2020) Timing of Oral P2Y₁₂ Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol 76(21):2450–2459. https://doi.org/10.1016/j.jacc.2020.08.053 (Epub 2020 Aug 31)CrossRefPubMed

15.

Ferrari R, Ford I, Fox K et al (2019) A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics. Am Heart J 210:98–107. https://doi.org/10.1016/j.ahj.2018.12.015 (Epub 2019 Jan 15)CrossRefPubMed

16.

Ferrari R, Ford I, Fox K et al (2020) Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet 396(10254):830–838. https://doi.org/10.1016/S0140-6736(20)31790-6CrossRefPubMed

17.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa612CrossRefPubMedPubMedCentral

18.

Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM (2020) ESC Scientific Document Group ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa575CrossRefPubMedPubMedCentral

19.

Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M (2020) ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa605CrossRefPubMed

20.

Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K (2020) ESC Scientific Document Group ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa554CrossRefPubMed

Title: Highlights from the European society of cardiology congress 2020
Authors: Pooneh Nabavizadeh
Dylan L. Steen
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Colchicine
Stroke
Transcatheter Aortic Valve Implantation
Empagliflozin
Myocardial Infarction
Heart Failure
Atrial Fibrillation
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02365-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Highlights from the European society of cardiology congress 2020

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Decreased size of the left anterior descending coronary artery is an independent predictor of deterioration in non-high-risk patients with acute pulmonary embolism

Safety and efficacy of rt-PA treatment for acute stroke in pseudoxanthoma elasticum: the first report

Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer

Incidence and characteristics of spontaneous platelet macro-aggregation in acute ischemic stroke

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection

Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page